Work

Supplementary Figure S3 from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

Year: 2023

Type: supplementary-materials

Abstract: Tarloxotinib-E inhibits ErbB family members phosphorylation and downstream signaling in EGFR, HER2 and NRG1 driven cell lines.

DOI: 10.1158/1078-0432.22478576

Authors: Adriana Estrada-Bernal, Anh T. Le, Andrea E. Doak, Vijaya G. Tirunagaru, Shevan Silva, Matthew R. Bull, Jeff B. Smaill, Adam V. Patterson, Chul Kim, Stephen V. Liu, Robert C. Doebele

Institutions: University of Colorado Anschutz, University of Auckland, Maurice Wilkins Centre, Georgetown University, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Funders: National Institutes of Health, Cancer Center, University of Colorado, Health Research Council of New Zealand, National Cancer Institute

Awards: G1565180698, G8440876798, SPORE in Lung Cancer, University of Colorado Cancer Center Support Grant

OpenAlex ID: W4361889437

Cites: 26

Cited by:

Related to: 10